Barbato MI, Bradford D, Ren Y, Aungst SL, et al. FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer. Clin Cancer Res 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949.
PMID: 38875108